Kancera AB - Product Pipeline Review - 2016

  • ID: 3802735
  • Company Profile
  • 40 pages
  • Global Markets Direct
1 of 3
Kancera AB - Product Pipeline Review - 2016

Summary

‘Kancera AB - Product Pipeline Review - 2016’, provides an overview of the Kancera AB’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Kancera AB, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

The author's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from their proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Kancera AB
- The report provides overview of Kancera AB including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Kancera AB’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Kancera AB’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Kancera AB’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Kancera AB
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Kancera AB’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 3
List of Tables

List of Figures

Kancera AB Snapshot

Kancera AB Overview

Key Information

Key Facts

Kancera AB - Research and Development Overview

Key Therapeutic Areas

Kancera AB - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Pipeline Products - Partnered Products

Partnered Products/Combination Treatment Modalities

Kancera AB - Pipeline Products Glance

Kancera AB - Early Stage Pipeline Products

Preclinical Products/Combination Treatment Modalities

Discovery Products/Combination Treatment Modalities

Kancera AB - Drug Profiles

KAN-0437757

Product Description

Mechanism of Action

R&D Progress

KAN-0438757

Product Description

Mechanism of Action

R&D Progress

KAN-0439834

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibodies to Target ROR-1 for Chronic Lymphocytic Leukemia and Melanoma

Product Description

Mechanism of Action

R&D Progress

KAN-0439221

Product Description

Mechanism of Action

R&D Progress

KAN-043936

Product Description

Mechanism of Action

R&D Progress

KAN-0439363

Product Description

Mechanism of Action

R&D Progress

KAN-0439365

Product Description

Mechanism of Action

R&D Progress

KAN-0439828

Product Description

Mechanism of Action

R&D Progress

KAN-0439829

Product Description

Mechanism of Action

R&D Progress

KAN-439782

Product Description

Mechanism of Action

R&D Progress

Small Molecule for Malaria

Product Description

Mechanism of Action

R&D Progress

Small Molecule for Schistosomiasis

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Inhibit HDAC6 for Oncology

Product Description

Mechanism of Action

R&D Progress

Kancera AB - Pipeline Analysis

Kancera AB - Pipeline Products by Target

Kancera AB - Pipeline Products by Route of Administration

Kancera AB - Pipeline Products by Molecule Type

Kancera AB - Pipeline Products by Mechanism of Action

Kancera AB - Recent Pipeline Updates

Kancera AB - Dormant Projects

Kancera AB - Discontinued Pipeline Products

Discontinued Pipeline Product Profiles

Small Molecules To Agonize GPR-119 For Type 2 Diabetes

Small Molecules To Inhibit SCD1 For Obesity And Diabetes

Kancera AB - Locations And Subsidiaries

Head Office

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer 40List of Tables

Kancera AB, Key Information

Kancera AB, Key Facts

Kancera AB - Pipeline by Indication, 2016

Kancera AB - Pipeline by Stage of Development, 2016

Kancera AB - Monotherapy Products in Pipeline, 2016

Kancera AB - Partnered Products in Pipeline, 2016

Kancera AB - Partnered Products/ Combination Treatment Modalities, 2016

Kancera AB - Preclinical, 2016

Kancera AB - Discovery, 2016

Kancera AB - Pipeline by Target, 2016

Kancera AB - Pipeline by Route of Administration, 2016

Kancera AB - Pipeline by Molecule Type, 2016

Kancera AB - Pipeline Products by Mechanism of Action, 2016

Kancera AB - Recent Pipeline Updates, 2016

Kancera AB - Dormant Developmental Projects,2016

Kancera AB - Discontinued Pipeline Products, 2016 37List of Figures

Kancera AB - Pipeline by Top 10 Indication, 2016

Kancera AB - Pipeline by Stage of Development, 2016

Kancera AB - Monotherapy Products in Pipeline, 2016

Kancera AB - Pipeline by Target, 2016

Kancera AB - Pipeline by Molecule Type, 2016

Kancera AB - Pipeline Products by Mechanism of Action, 2016
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll